Sana Biotechnology
Nate Hardy, MBA, is Senior Vice President and Chief Financial Officer of Sana Biotechnology.
Most recently Nate was Vice President of Finance at Juno Therapeutics where he led the Business, Financial Planning and Treasury organizations. Prior to joining Juno, Nate was at Amgen for over 10 years and served in a variety of senior finance and operations leadership positions, culminating as the Executive Director and Head of Corporate Finance. During his time at Juno and Amgen, he led resource allocation activities across the organizations, helped drive a large-scale business transformation at Amgen, and was part of various acquisitions and divestitures. Prior to Amgen, Nate had various roles within finance at General Electric and Sprint Telecom.
He obtained a BS in finance from the University of Utah and a Master’s in business administration from the University of Notre Dame.
Sana Biotechnology
2 followers
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy.